$387.61 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter

Share on StockTwits

Wall Street analysts forecast that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will report sales of $387.61 million for the current fiscal quarter, according to Zacks. Eleven analysts have provided estimates for BioMarin Pharmaceutical’s earnings. The lowest sales estimate is $379.00 million and the highest is $397.50 million. BioMarin Pharmaceutical posted sales of $373.45 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.8%. The firm is scheduled to announce its next earnings results after the market closes on Thursday, April 25th.

According to Zacks, analysts expect that BioMarin Pharmaceutical will report full-year sales of $1.69 billion for the current fiscal year, with estimates ranging from $1.66 billion to $1.71 billion. For the next financial year, analysts expect that the company will report sales of $1.95 billion, with estimates ranging from $1.78 billion to $2.11 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, February 21st. The biotechnology company reported ($0.02) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.07. The company had revenue of $353.00 million for the quarter, compared to the consensus estimate of $377.35 million. BioMarin Pharmaceutical had a negative return on equity of 2.79% and a negative net margin of 5.18%. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 EPS.

A number of research firms recently issued reports on BMRN. BidaskClub raised BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, January 19th. Wedbush reissued an “outperform” rating and set a $127.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 7th. ValuEngine raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald boosted their price target on BioMarin Pharmaceutical to $131.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Finally, Zacks Investment Research lowered BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, March 1st. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company. BioMarin Pharmaceutical presently has an average rating of “Buy” and an average price target of $114.82.

In other news, CEO Jean Jacques Bienaime sold 4,000 shares of the business’s stock in a transaction dated Thursday, February 14th. The shares were sold at an average price of $95.20, for a total transaction of $380,800.00. Following the completion of the sale, the chief executive officer now directly owns 292,290 shares of the company’s stock, valued at $27,826,008. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director V Bryan Lawlis sold 2,150 shares of the company’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $89.76, for a total transaction of $192,984.00. Following the completion of the sale, the director now directly owns 21,310 shares of the company’s stock, valued at $1,912,785.60. The disclosure for this sale can be found here. Insiders have sold 94,011 shares of company stock worth $8,588,208 in the last quarter. Company insiders own 1.90% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Financial Gravity Wealth Inc. purchased a new stake in BioMarin Pharmaceutical in the 1st quarter worth approximately $194,000. Gulf International Bank UK Ltd grew its holdings in BioMarin Pharmaceutical by 1.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 45,360 shares of the biotechnology company’s stock worth $4,029,000 after acquiring an additional 600 shares during the last quarter. IFM Investors Pty Ltd grew its holdings in BioMarin Pharmaceutical by 15.1% in the 1st quarter. IFM Investors Pty Ltd now owns 11,770 shares of the biotechnology company’s stock worth $1,046,000 after acquiring an additional 1,545 shares during the last quarter. Appleton Partners Inc. MA lifted its position in shares of BioMarin Pharmaceutical by 26.7% in the 1st quarter. Appleton Partners Inc. MA now owns 6,389 shares of the biotechnology company’s stock worth $568,000 after purchasing an additional 1,348 shares during the period. Finally, CMH Wealth Management LLC lifted its position in shares of BioMarin Pharmaceutical by 105.6% in the 1st quarter. CMH Wealth Management LLC now owns 27,283 shares of the biotechnology company’s stock worth $2,424,000 after purchasing an additional 14,010 shares during the period.

Shares of BMRN stock opened at $83.71 on Tuesday. BioMarin Pharmaceutical has a 1-year low of $79.13 and a 1-year high of $106.74. The company has a current ratio of 3.93, a quick ratio of 2.92 and a debt-to-equity ratio of 0.28. The firm has a market cap of $15.03 billion, a PE ratio of -253.67 and a beta of 1.51.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read More: Balanced Fund

Get a free copy of the Zacks research report on BioMarin Pharmaceutical (BMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.